Shock Therapeutics Biotech

STBI is an early stage biopharmaceutical company founded to advance the development of a revolutionary medical discovery that could reverse the condition of shock, buying time for life-saving critical care interventions.

THE PROBLEM

Hypovolemic Shock (Hemorrhagic Shock or Shock) is the condition which precedes death in almost all cases of fatal injury & trauma.

The U.S.

Over 250,000

Leading cause of death under 45 annually killing

CDC

The World

5.8

Million

Annually injury and violence kill an estimated

WHO

The Military

Preventable

Deaths

Leading cause of potentially

Eastridge & Holcomb 2019

Unfortunately, once shock sets in, it is incredibly hard to reverse. We believe this is because the current treatment options are for the trauma and symptoms of shock - not for shock itself.

info@shockbiotech.com

1100 Wicomico Street

Baltimore, MD 21230

  • LinkedIn Social Icon
  • Twitter Social Icon
  • Facebook Social Icon

© 2020 Shock Therapeutics Biotechnologies, Inc.

Proudly Founded & Headquartered in Baltimore, Maryland